New Almac Liver Disease Panel



Almac Liver Disease Panel: Background

Almac is in the process of developing and analytically validating a liver disease panel for prospective clinical trial use for Steatotic Liver Disease.

Almac's Liver Disease Panel is a qpCR genotyping panel for 7 of the most common steatotic liver disease gene research targets, including 10 germline SNPs. The panels intended use is to determine molecular eligibility for MASLD / MASH Trials.

The panel is designed to process up to 12 specimens per run with a turnaround time of 3 - 5 days * from specimen receipt at Almac Diagnostic Services Craigavon, UK Lab.

Almac Liver Disease Panel: Content Customisation

The panel has the option to be customised to add additional genes of interest for your individual biomarker drug development programme. The additional genes of interest would need to be validated for prospective clinical trial use alongside the other 10 SNP targets present. Almac can facilitate this custom development, tailored to your exact clinical trial requirements, at additional time and cost.

ALMAC LIVER DISEASE PANEL: TARGET GENES AND SNPS OF INTEREST

ASSAY	GENE SYMBOL	SNP ID	ALLELE	VARIANT	FUNCTION
1	PNPLA3	rs738409	C>G	I148M	Risk Variant
2	HSD17B13	rs72613567	T>TA insertion	truncated protein	Protective Variant
3	HSD17B13	rs6834314	A>G	non-coding region	Protective Variant
4	HSD17B13	rs62305723	A>G	P260S	Protective Variant
5	TM6SF2	rs58542926	G>A	E167K	Risk Variant
6	SERPINA1	rs28929474	G>A	E342K	Risk Variant
7	MBOAT7	rs641738	C>T	3'UTR	Risk Variant
8	GCKR	rs1260326	T>C	P446L	Risk Variant
9	GCKR	rs780094	C>T	non-coding region	Risk Variant
10	MARC1	rs2642438	G>A	A165T	Protective Variant

ALMAC LIVER DISEASE PANEL: AT A GLANCE

CATEGORY	SPECIFICATION
Intended Use	IUO
Manufacture	Almac Designed Assays
Laboratory Delivery Location	Craigavon, UK. CLIA / CAP accredited clinical testing lab
Sample Type	Blood
Sample Throughput	12 (optimal batch)
Assay Content	10 assays + option to customise panel. Option to add additional targets for your drug development programme
Regulatory Pathway	Validated for use in global clinical trials, excluding China. Potential to leverage Almac Health Institution pathway option for faster EU trial enrolment
Turnaround Time	3-5 Days *Depending on batch sizes

Register Your Interest

Scan to find out more

Register your interest here and Almac will reach out to you in 2027 when the panel becomes available.
almacgroup.com/diagnostics/LiverPanel

AM5350